A new clinical trial demonstrated that obicetrapib, an investigational cholesteryl ester transfer protein inhibitor, effectively reduced low-density lipoprotein cholesterol by 29.9% in high-risk cardiovascular patients already on maximum lipid-lowering therapy. This offers a potential additional strategy to further decrease LDL cholesterol levels.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
